Asthma and COPD Management

Introduction to Pulmicort Dosage

For patients with mild-to-moderate asthma, the American Thoracic Society recommends a daily dose of 200-600 mcg of Pulmicort, either as a single dose or divided into two doses, via a Dry Powder Inhaler (Turbuhaler) 1
For patients with moderate-to-severe asthma, the American Thoracic Society recommends a daily dose of 600-1200 mcg of Pulmicort, divided into two doses, via a Dry Powder Inhaler (Turbuhaler) 1
For patients with severe asthma, the American Thoracic Society recommends a daily dose of >1200 mcg of Pulmicort, divided into two doses, via a Dry Powder Inhaler (Turbuhaler) 1

The first treatment with Pulmicort should always be administered under supervision, and patients should receive written instructions for ongoing use, as recommended by the European Respiratory Society and the British Thoracic Society 2, 2
After achieving asthma control, the dose of Pulmicort should be titrated downward to the minimum effective dose, as recommended by the American College of Chest Physicians 1

For COPD patients with severe episodes, the European Respiratory Society recommends considering a combination of a β-agonist with ipratropium bromide 500 µg 4-6 hourly 2
Budesonide may be considered in COPD patients with frequent exacerbations despite optimal bronchodilator therapy, with evaluation of response after 6 weeks and continuation only if objective improvement is documented (FEV₁ improvement ≥10% predicted and/or >200 mL) 3
The European Respiratory Society suggests considering a trial of budesonide in COPD patients with a fast rate of FEV₁ decline (>50 mL/year) 3

Patients should be educated on proper inhaler technique and regularly checked to ensure correct use, as emphasized by the National Asthma Education and Prevention Program
The American College of Chest Physicians recommends evaluating objective improvement in COPD patients after 6 weeks of treatment with Pulmicort, and continuing only if improvement is documented 1
The European Respiratory Society recommends that budesonide is not used for as-needed (PRN) use in asthma or COPD management, as it is a controller medication that requires regular scheduled dosing to be effective 2
Budesonide inhalation suspension is indicated for maintenance treatment of asthma as controller therapy, not for relief of acute symptoms, with FDA-approved dosing recommendations 2
Regular nebulized bronchodilator treatment should only be undertaken after formal evaluation of its benefit and where treatment with a hand-held inhaler at appropriate doses has failed, according to the British Thoracic Society 2